See the DrugPatentWatch profile for tigecycline

Based on the information provided, there is no specific study or evidence that directly links the changes in aspartate transaminase (AST) and alanine transaminase (ALT) levels with the administration of tigecycline. Therefore, it is not possible to provide a definitive answer to this question.

However, it is important to note that changes in AST and ALT levels can be indicative of liver damage or injury. Tigecycline, like other antibiotics, can cause liver enzyme elevations [1]. According to the drug label, increased AST and ALT levels have been reported in some tigecycline-treated patients [2]. However, the label does not provide specific information on the extent of these changes or their clinical significance.

In general, healthcare professionals monitor liver function tests, including AST and ALT, in patients receiving tigecycline as part of routine care [3]. Any significant changes in these levels would be evaluated in the context of the patient's overall clinical condition and other potential contributing factors.

In conclusion, while some cases of increased AST and ALT levels have been reported in tigecycline-treated patients, there is no specific information available on how these enzyme levels change with tigecycline administration. Therefore, it is crucial to monitor liver function tests regularly in patients receiving tigecycline.

Sources:
[1] DrugPatentWatch.com, "Tigecycline (Tygacil): Side Effects, Dosage, and Interactions", <https://www.drugpatentwatch.com/drugs/tigecycline>.
[2] U.S. Food and Drug Administration (FDA), "Tygacil (tigecycline) prescribing information", <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s013s014lbl.pdf>.
[3] UpToDate, "Tigecycline: drug information", <https://www.uptodate.com/contents/tigecycline-drug-information>.